Author/Authors :
Nikitenko, N.A N.F. Gamaleya Federal National Research Center for Epidemiology and Microbiology, Moscow, Russia , Gureeva, E.S Volgograd State Medical University, Volgograd, Russia , Ozerov, A.A Volgograd State Medical University, Volgograd, Russia , Tukhvatulin, A.I Volgograd State Medical University, Volgograd, Russia , Izhaeva, F.M N.F. Gamaleya Federal National Research Center for Epidemiology and Microbiology, Moscow, Russia , Prassolov, V.S Engelhardt Institute of Molecular Biology - Russian Academy of Sciences, Moscow, Russia , Deryabin, P.G N.F. Gamaleya Federal National Research Center for Epidemiology and Microbiology, Moscow, Russia , Novikov, M.S Volgograd State Medical University, Volgograd, Russia , Logunov, D.Y N.F. Gamaleya Federal National Research Center for Epidemiology and Microbiology, Moscow, Russia
Abstract :
Adenovirus infections are characterized by widespread distribution. The lack of causal therapy, which is effective in treating this group of diseases, explains the need for new therapeutic drugs. Notably, anti-adenovi-ral activity of [4-(phenoxy)benzyl]-5-(phenylamino)-6-azauracil, 1-[4-(phenoxy)benzyl]-5-(morpholino) uracil, 1-[4-(4-chlorophenoxy)benzyl]-5-(morpholino) uracil, and 1-[4-(4-fluorophenoxy)-benzyl]-5-(morpholino) uracil was observed.
Keywords :
inhibitors of adenovirus replication , adenovirus replication , 5-aminouracil derivatives , Human adenovirus
